<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446793</url>
  </required_header>
  <id_info>
    <org_study_id>CRDF-01E</org_study_id>
    <nct_id>NCT04446793</nct_id>
  </id_info>
  <brief_title>Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer</brief_title>
  <official_title>An Expanded Access Program of Onvansertib in Combination With FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients With KRAS-Mutated Metastatic Colorectal Cancer (mCRC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiff Oncology</source>
  <brief_summary>
    <textblock>
      This is an expanded access program for eligible participants designed to provide access to
      onvansertib in combination with FOLFIRI and bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>KRAS Gene Mutation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onvansertib</intervention_name>
    <description>15 mg/m^2 will be administered orally on Day 1 to Day 5 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>FOLFIRI (180 mg/m^2 irinotecan, 400 mg/m^2 leucovorin, 400 mg/m^2 bolus 5-fluorouracil [5-FU], and 2400 mg/m^2 continuous intravenous infusion 5-FU over 46 hours) will be administered intravenously on Day 1 of every 14 day treatment course. There will be two 14-day courses of treatment in each 28 day cycle.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is NOT eligible for other clinical trials currently open in the region

          -  Participant has failed or progressed on standard of care systemic therapy

          -  FOLFIRI (with or without 5FU bolus and continuous infusion)/bevacizumab plus
             onvansertib is appropriate for the participant as determined by the treating
             physician, including participants who have previously been treated with FOLFIRI

          -  Histologically confirmed metastatic and unresectable CRC with a confirmed KRAS
             mutation

          -  Age â‰¥ 18 years

        Women of Child-bearing Potential

          -  Women of child-bearing potential (WOCBP) must agree to use method(s) of contraception

          -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L
             or equivalent units of human chorionic gonadotropin) within 24 hours prior to the
             start of onvansertib treatment

          -  If sexually active, the participant must agree to use contraception considered
             adequate and appropriate by the treating physician during the period of onvansertib
             administration

        Exclusion Criteria:

          -  Participant has not recovered from minor or major surgery and less than 6 weeks out
             from major surgery

          -  Participant has active Hepatitis B or C infection

          -  Participant has a known history of testing positive for human immunodeficiency virus
             or having been diagnosed with acquired immunodeficiency syndrome

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, clinically significant non-healing or healing wounds, symptomatic
             congestive heart failure Class II or higher according to the New York Heart
             Association Functional Classification, unstable angina pectoris, significant pulmonary
             disease (shortness of breath at rest or mild exertion), that would limit compliance
             with study requirements

          -  Abnormal glucuronidation of bilirubin, known Gilbert's syndrome

          -  Participants with any other serious or uncontrolled medical disorder, active
             infection, physical exam finding, laboratory finding, altered mental status, or
             psychiatric condition that, in the opinion of the treating physician, would
             substantially increase risk to their well-being

          -  Any condition that, in the opinion of the treating physician, would substantially
             increase risk to their well-being
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>CRDF-01e Expanded Access Team</last_name>
    <phone>800-772-3125</phone>
    <phone_ext>154301</phone_ext>
    <email>CRDFEAP@prahs.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>KRAS-Mutation</keyword>
  <keyword>Onvansertib</keyword>
  <keyword>PCM-075</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>5-Fluoruracil</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

